 Lipocine Inc NASDAQ: LPCN has entered into an exclusive licensing agreement with Antares Pharma Inc NASDAQ: ATRS to commercialize Tlando in the U.S. Tlando is an oral testosterone product for testosterone replacement therapy in adult males indicated for conditions associated with a deficiency or absence of endogenous testosterone. 